InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.13
(
-0.18%
)
Bitcoin
66,639.00
(
0.68%
)
Post# of 2341349
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

HiddenGem69

Send PM Follow Ignore
Followers 40
Posts 1456
Boards Moderated 0
Alias Born 09/23/2013

HiddenGem69

Re: HiddenGem69 post# 1213021

Monday, 09/30/2013 11:08:03 AM

Monday, September 30, 2013 11:08:03 AM

Post# of 2341349
$NVLX Those results included an increase of about 4 months in median survival time over gemcitabine alone versus the 1.8 months seen with the ABRAXANE-gemcitabine combination. The results included a 100% increase in the one-year survival rate as compared to gemcitabine versus a 59% increase for the ABRAXANE-gemcitabine combination. The results obtained with Nuvilex's treatment are even more noteworthy given that only one-third of the dose of ifosfamide normally used to treat other types of cancer was used in the Phase II trials for advanced, inoperable pancreatic cancer.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up